267 related articles for article (PubMed ID: 22547089)
1. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.
Tun NM; Villani GM
J Thromb Thrombolysis; 2012 Oct; 34(3):347-59. PubMed ID: 22547089
[TBL] [Abstract][Full Text] [Related]
2. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
[TBL] [Abstract][Full Text] [Related]
3. [Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case].
Ojeda-Uribe M; Brunot A; Issler M
Rev Med Chil; 2005 Nov; 133(11):1349-54. PubMed ID: 16446859
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura.
Albaramki JH; Teo J; Alexander SI
Pediatr Nephrol; 2009 Sep; 24(9):1749-52. PubMed ID: 19399522
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for thrombotic thrombocytopenic purpura.
Cataland SR; Wu HM
Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Sadler JE
Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.
Chemnitz JM; Uener J; Hallek M; Scheid C
Ann Hematol; 2010 Oct; 89(10):1029-33. PubMed ID: 20422413
[TBL] [Abstract][Full Text] [Related]
10. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
[TBL] [Abstract][Full Text] [Related]
11. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Coppo P; Veyradier A
Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature.
Montoya RC; Poiesz BJ
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):338-41. PubMed ID: 22498981
[TBL] [Abstract][Full Text] [Related]
13. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab.
Caramazza D; Quintini G; Abbene I; Malato A; Saccullo G; Lo Coco L; Di Trapani R; Palazzolo R; Barone R; Mazzola G; Rizzo S; Ragonese P; Aridon P; Abbadessa V; Siragusa S
Transfusion; 2010 Dec; 50(12):2753-60. PubMed ID: 20576013
[TBL] [Abstract][Full Text] [Related]
14. Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.
Iioka F; Shimomura D; Ishii T; Maesako Y; Ohgoe K; Nakamura F; Matsuo S; Ohno H
Int J Hematol; 2012 Oct; 96(4):506-12. PubMed ID: 22878941
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
Elliott MA; Heit JA; Pruthi RK; Gastineau DA; Winters JL; Hook CC
Eur J Haematol; 2009 Oct; 83(4):365-72. PubMed ID: 19508684
[TBL] [Abstract][Full Text] [Related]
16. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
Cataland SR; Jin M; Lin S; Kraut EH; George JN; Wu HM
Am J Hematol; 2008 Dec; 83(12):911-5. PubMed ID: 18821711
[TBL] [Abstract][Full Text] [Related]
17. [Thrombotic-thrombocytopenic purpura].
Hellmann M; Hallek M; Scharrer I
Internist (Berl); 2010 Sep; 51(9):1136, 1138-44. PubMed ID: 20689903
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange].
Koshino M; Kudou D; Okoshi Y; Obara N; Simizu S; Mukai HY; Suzukawa K; Hasegawa Y; Kojima H; Nagasawa T; Chiba S
Rinsho Ketsueki; 2010 Feb; 51(2):127-31. PubMed ID: 20379104
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
[TBL] [Abstract][Full Text] [Related]
20. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA
Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
